Study S003267

An Open-Label, Parallel-Group, Single-Dose Pharmacokinetic Study of HRS-4729 Injection in Healthy Participants and Patients With Renal Impairment

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07807059
Study type: INTERVENTIONAL
Allocation: NON_RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: RECRUITING
Enrollment: 32
Start: 2026-09-09
Primary completion: 2027-03-15
Lead sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
Conditions: Overweight/Obesity; Metabolic Dysfunction-associated Steatotic Liver Disease/Steatohepatitis (MASLD/MASH); Type 2 Diabetes Mellitus
Interventions: DRUG:HRS-4729
Results posted: FALSE
Individual participant data sharing: UNDECIDED

Registered primary outcomes

Cmax [assessed up to approximately 4 weeks post-dose;]
AUC0-t [assessed up to approximately 4 weeks post-dose]
AUC0-inf. [assessed up to approximately 4 weeks post-dose]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.